Table 1. Baseline characteristics of each treatment group.

Variable		CTX only		Trastuzumab + CTX		Total		P-value
Number of patients		45		70		115
Gender
	Male	34	75.6%	52	74.3%	86	74.8%	0.878
	Female	11	24.4%	18	25.7%	29	25.2%
Age
	Median age, years (range)	58 (37–72)		59 (30–80)		58 (30–80)		0.884*
BMI
	Median, kg/m2 (range)	22.7 (16.7–35.0)		21.4 (13.8–32.5)		21.9 (13.8–35.0)		0.059*
Baseline LVEF
	Median, % (range)	66 (57–75)		65 (57–75)		66 (57–75)		0.307*
Maximally decreased LVEF from baseline LVEF
	Median, % (range)	6 (1–12)		7 (1–21)		6 (1–21)		0.279*
Total treatment cycles
	Median, number (range)	8 (2–92)		9 (1–62)		8 (1–92)		0.827*
Hypertension
	Yes	12	26.7%	18	25.7%	30	26.1%	0.910
	No	33	73.3%	52	74.3%	85	73.9%
Underlying cardiac disease
	Yes	1	2.2%	3	4.3%	4	3.5%	>0.99†
	No	44	97.8%	67	95.7%	111	96.5%
Diabetes
	Yes	5	11.1%	8	11.4%	13	11.3%	>0.99†
	No	40	88.9%	62	88.6%	102	88.7%
Hyperlipidemia
	Yes	0	0.0%	2	2.8%	2	1.7%	0.519†
	No	45	100%	68	97.2%	113	98.3%
Cerebrovascular disease
	Yes	1	2.2%	3	4.3%	4	3.5%	>0.99†
	No	44	97.8%	67	95.7%	111	96.5%
Smoking
	Current	15	33.3%	20	28.6%	35	30.4%	0.862
	Former	11	24.4%	18	25.7%	29	25.2%
	Never	19	42.3%	32	45.7%	51	44.4%

BMI, body mass index; CTX, cytotoxic chemotherapy; LVEF, left ventricular ejection fraction; *Analyzed by the Mann-Whitney U test; † Analyzed by the Fisher’s exact test